Thomas Hengelage

In Vitro Studies with Purified Components Reveal Signal Recognition Particle (SRP) and SecA/SecB as Constituents of Two Independent Protein-targeting Pathways of<i>Escherichia coli</i>

Hans‐Georg Koch, Thomas Hengelage, Christoph Neumann‐Haefelin et al. · Molecular Biology of the Cell · 1999 · 157 citations

Life Sciences, Biochemistry, Molecular Biology +17

Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

Irene Braña, Geoffrey I. Shapiro, Melissa L. Johnson et al. · Journal of Clinical Oncology · 2021 · 73 citations

Medicine, Oncology, Pharmacology +16

Requirements for the Translocation of Elongation-arrested, Ribosome-associated OmpA across the Plasma Membrane ofEscherichia coli

M Behrmann, Hans‐Georg Koch, Thomas Hengelage et al. · Journal of Biological Chemistry · 1998 · 50 citations · Full text

Life Sciences, Microbiology, Molecular Biology +12

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

Paul Hamberg, Margaret M. Woo, Lin‐Chi Chen et al. · Cancer Chemotherapy and Pharmacology · 2011 · 45 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12

Dose-Dependent Acute and Sustained Renal Effects of the Endothelin Receptor Antagonist Avosentan in Healthy Subjects

Jessica Smolander, Bruno Vogt, Marc Maillard et al. · Clinical Pharmacology & Therapeutics · 2009 · 36 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17